Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    NIH REACH Program to Speed Commercialization of Health Technologies

    By Global Biodefense StaffMarch 24, 2015
    Share
    Facebook LinkedIn Reddit Email

    The National Institutes of Health has selected three new proof-of-concept hubs to help speed the translation of basic biomedical discoveries into commercial products, such as new drugs, devices, and diagnostics, to improve patient care and enhance health.

    The hubs are part of the NIH-supported Research Evaluation and Commercialization Hubs (REACH) program and will be funded at $9 million over three years.

    REACH is based on an initiative created by the NIH’s National Heart, Lung, and Blood Institute (NHLBI) called the NIH Centers for Accelerated Innovations (NCAI). These centers are a unique public-private partnership whose objective is to change how to identify and develop innovations with scientific and commercial potential.

    The effort utilizes industry-style project management to arrive at technologies that are poised to launch. With the addition of the REACH, NIH has created a nationwide network of six centers and hubs to develop best practices in translating academic innovations into products to improve health.

    The new REACH awardees are:

    • The Long Island Bioscience Hub: Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, New York
    • The University of Louisville, Kentucky
    • The University of Minnesota, Minneapolis

    The existing NCAI awardees are:

    • Boston Biomedical Innovation Center: Brigham and Women’s Hospital, Boston Children’s Hospital, Massachusetts General Hospital, and President and Fellows of Harvard College
    • Cleveland Clinic Innovation Accelerator: The Cleveland Clinic Lerner College of Medicine; Case Western Reserve University, Cleveland; Cincinnati Children’s Hospital; The Ohio State University, Columbus; and University of Cincinnati
    • University of California BRAID Center for Accelerated Innovation: University of California, Los Angeles; University of California, Davis; University of California, Irvine; University of California, San Diego; and University of California, San Francisco

    The hubs will foster the development of therapeutics, preventatives, diagnostics, devices, and tools that address diseases within the NIH’s mission. Each hub will provide funding for feasibility studies and coordinated access to expertise in areas required for early stage technology development, including scientific, regulatory, reimbursement, business, legal, and project management. In addition, the hubs will provide skills development and hands-on experience in entrepreneurism.

    The REACH program will take advantage of the NCAI’s established infrastructure and relationships, including partnerships with the U.S. Food and Drug Administration, the United States Patent Office, and the Centers for Medicare & Medicaid Services.

    The REACHs and NCAIs will work collaboratively, share resources when appropriate, and develop best practices that will be made available to the public. To enhance the scope and impact of the NIH investment, each REACH has secured non-federal funding equal to or greater than the NIH award and developed partnerships with other regional public and private organizations.

    Antimicrobials Awards NIH
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleNational Preparedness and Response Science Board Meeting
    Next Article Grants Available for National Syndromic Surveillance Program

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy